<DOC>
	<DOCNO>NCT00744731</DOCNO>
	<brief_summary>The purpose study obtain long-term safety tolerability information carisbamate add-on therapy treatment partial onset seizure patient epilepsy . Seizure count obtain measure rate seizure patient study .</brief_summary>
	<brief_title>An Open-Label Extension Study Safety Tolerability Carisbamate Add-On Therapy Patients With Partial Onset Seizures</brief_title>
	<detailed_description>CARISEPY3014 open-label extension study follow double-blind study CARISEPY3013 ( NCT00740623 ) . In open label study CARISEPY3014 , physician patient know name assign study medication . In double blind study CARISEPY-3013 , neither physician patient know name assign study medication . Patients complete 14-week double-blind treatment phase study CARISEPY3013 eligible enter open-label extension study patient transition 1-week blinded period open-label carisbamate . There 1 week blind transition patient take blind study medication ; , patient take unblinded , open-label study medication . Safety assessment include monitoring frequency , severity , time adverse event , clinical laboratory test result , 12-lead electrocardiogram ( ECG ) recording , vital sign measurement , physical neurologic examination , Physician Withdrawal Checklist symptom withdrawal patient taper and/or discontinue study drug , pregnancy test females childbearing potential . Seizure count obtain every visit . The Quality Life Epilepsy-31 Patient Inventory questionnaire administer study . A Medical Resource utilization questionnaire use obtain cost-effectiveness information carisbamate administer twice study . There statistical test hypothesis study . Carisbamate tablet take twice daily 2 equally divided dos , without food , take noncarbonated water . During first week study , patient take blind transition study medication thereafter take target dosage 800 mg/day unblinded , open-label study medication . The dosage study medication range 400 1,200 mg/day . Patients receive treatment 1 year potential receive treatment longer .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Epilepsy , Complex Partial</mesh_term>
	<mesh_term>Epilepsy , Partial , Motor</mesh_term>
	<criteria>Must complete 14week doubleblind treatment phase study CARISEPY3013 must willing/able follow restriction prohibition protocol must able complete patient diary correctly ( patient legally acceptable representative ) must sign informed consent form indicate agreement participate study ( patient legally acceptable representative ) adolescent capable understanding nature study must provide assent participate study Patients complete 14week doubleblind treatment phase study CARISEPY3013 .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Partial-onset Seizures</keyword>
	<keyword>Simple Partial Seizures</keyword>
	<keyword>Complex Partial Seizures</keyword>
</DOC>